Stock screenerAll disclosures →
EDGAR →
INCY
Conviction 91HealthcareScan · Thu, Sep 24, 2026Incyte Corp (INCY) closed at $124.41 (-0.18%) on Sep 24, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 50, RS Rating 89, -4.3% from its 52-week high, +22.7% year to date. Sector: Healthcare · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH.
INCY$124.41-0.18%
ResistanceSupportVol 14Insider sellCongress buyCongress sell2
2
Vol MA14 1.62M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price124.41
Change-0.18%
Gap+0.17%
Rel volume1.54×
Avg volume1.53M
Avg $ vol191.09M
SMA 20125.07
SMA 50123.10
SMA 200106.11
Price vs 50+1.06%
Price vs 200+17.24%
MA stackbullish
50/200 cross—
Supertrendup · 118.54
RSI (14)50
MACD hist-0.22
MACD cross—
Stoch %K / %D51 / 56
ADX (14)15
+DI / −DI24 / 18
RSI divergence—
MACD divergence—
ATR %2.68%
ADR %2.56%
52w high129.93
52w low81.66
From 52w high-4.25%
Above 52w low+52.35%
New 52w highNo
SqueezeOn · 2d
Bollinger width6.57%
%B0.42
Donchian pos44.27%
Donchian high130.00
Donchian low119.97
AVWAP (52w high)124.31
vs AVWAP high+0.08%
AVWAP (52w low)103.53
vs AVWAP low+20.17%
OBV trendDown
Chaikin MF (20)-0.02
Today vs 20d1.54×
Avg vol (14d)1.62M
Avg vol (20d)1.53M
Avg $ vol (20d)191.09M
Market cap24.85B
RS Rating89 / 99
RS 3m (vs SPY)+11.21%
RS 6m (vs SPY)+18.07%
RS line new highNo
Trend template8/8
Technical rank79.5
1 week-2.52%
1 month-4.09%
3 months+15.70%
6 months+34.89%
1 year+47.16%
YTD+22.67%
P/E19.32
P/B4.42
P/S4.83
P/FCF18.21
EPS6.41
Div yield—
ROE22.88%
ROA17.53%
Debt/Eq0.18
Current3.68
EV/EBITDA13.93
Gross margin—
Net margin25.03%
Rev growth21.22%
EPS growth3844.96%
Price target130.79
Target upside5.13%
Analyst ratingBuy
Institutional110.81%
Ent. value22.4B
Revenue1.27B
Net income303.33M
Gross profit—
Free cash flow1.36B
IndustrySERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
ExchangeNasdaq
Shares out199.78M
Employees2.84K
ListedWed, Nov 3, 1993
Free float166.24M
Float %83.5%
Short interest9.36M
Days to cover7.7d
Short volume63.6%
Squeeze score60 / 100
Next earnings—
EPS forecast—
Last EPS vs est$2.80 vs $1.76
Last surprise+59.1% beat
Setup gradeA+
Conviction91 / 100
Pattern quality—
Tech rank79.5 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance130.40
Support116.67
Days since event—
Candle confirm—
Financials as of Tue, Mar 31, 2026 · quarterly.
Recent news
- FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This WeekStocktwits · Mon, Sep 21, 2026
- Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in AustraliaPR Newswire · Sun, Sep 20, 2026
- Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales TargetMarketbeat · Sun, Sep 20, 2026
Congress activity
Disclosed STOCK Act trades in INCY · 1 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Rob Bresnahan house · PA · traded 2025-05-15 | Sell | $1K–$15K | 2025-05-15 | 2025-05-31 |
Insider activity
SEC Form 4 transactions in INCY · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
CAGNONI PABLO J President, Global Head of R&D · Common Stock · 2026-09-15 | Exercise | 2.96K | $183K | 2026-09-15 | 2026-09-17 |
CAGNONI PABLO J President, Global Head of R&D · Common Stock · 2026-09-15 | Exercise | 4.55K | $278K | 2026-09-15 | 2026-09-17 |
CAGNONI PABLO J President, Global Head of R&D · Common Stock · 2026-09-15 | Exercise | 6.48K | $416K | 2026-09-15 | 2026-09-17 |
CAGNONI PABLO J President, Global Head of R&D · Common Stock · 2026-09-15 | Exercise | 9.23K | $664K | 2026-09-15 | 2026-09-17 |
CAGNONI PABLO J President, Global Head of R&D · Common Stock · 2026-09-15 | Sell | 9.23K | $1.1M | 2026-09-15 | 2026-09-17 |
CAGNONI PABLO J President, Global Head of R&D · Common Stock · 2026-09-15 | Sell | 13.98K | $1.7M | 2026-09-15 | 2026-09-17 |
CAGNONI PABLO J President, Global Head of R&D · Employee Stock Option (right to buy) · 2026-09-15 | Exercise | 2.96K | — | 2026-09-15 | 2026-09-17 |
CAGNONI PABLO J President, Global Head of R&D · Employee Stock Option (right to buy) · 2026-09-15 | Exercise | 4.55K | — | 2026-09-15 | 2026-09-17 |
CAGNONI PABLO J President, Global Head of R&D · Employee Stock Option (right to buy) · 2026-09-15 | Exercise | 6.48K | — | 2026-09-15 | 2026-09-17 |
CAGNONI PABLO J President, Global Head of R&D · Employee Stock Option (right to buy) · 2026-09-15 | Exercise | 9.23K | — | 2026-09-15 | 2026-09-17 |
SEC filings
EDGAR filings in INCY · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.